US2008009022A1PendingUtilityA1

Immunization of dairy cattle with chimeric gapC protein against streptococcus infection

63
Assignee: UNIV SASKATCHEWANPriority: Jun 12, 2000Filed: Jul 9, 2007Published: Jan 10, 2008
Est. expiryJun 12, 2020(expired)· nominal 20-yr term from priority
Inventors:Andrew A. PotterJose Perez-CasalMichael Fontaine
C07K 2319/00A61K 38/00C07K 14/315G01N 2469/20A61K 48/00G01N 33/56944A61K 2039/53A61P 31/04A61K 39/00
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The recombinant production of Gap4, a chimeric GapC plasmin binding protein comprising the entire amino acid sequence of the Streptococcus dysgalactiae GapC protein in addition to unique amino acid sequences from the Streptococcus parauberis and Streptococcus agalactiae GapC proteins, is described. Also described is the use of Gap4 chimeric GapC protein in vaccine compositions to prevent or treat streptococcal infections in general and mastitis in particular.

Claims

exact text as granted — not AI-modified
1 . A method of detecting  Streptococcus  antibodies in a biological sample, comprising: 
 (a) reacting said biological sample with a multiple epitope fusion polypeptide comprising more than one  Streptococcus  GapC epitope from more than one  Streptococcus  species, under conditions which allow said  Streptococcus  antibodies, when present in the biological sample, to bind to said sequence to form an antibody/antigen complex; and    (b) detecting the presence or absence of said complex, and thereby detecting the presence or absence of  Streptococcus  antibodies in said sample.    
     
     
         2 . The method of  claim 1 , wherein said multiple epitope fusion polypeptide comprises a GapC epitope from more than one  Streptococcus  species selected from the group consisting of  Streptococcus dysgalactiae, Streptococcus agalactiae, Streptococcus uberis, Streptococcus parauberis , and  Streptococcus iniae.    
     
     
         3 . The method of  claim 2 , wherein said multiple epitope fusion polypeptide comprises GapC epitopes from  Streptococcus dysgalactiae, Streptococcus agalactiae  and  Streptococcus parauberis.    
     
     
         4 . The method of  claim 3 , wherein the GapC epitopes in said multiple epitope fusion polypeptide are separated by a spacer amino acid sequence.  
     
     
         5 . The method of  claim 1 , wherein said multiple epitope fusion polypeptide comprises an epitope from a  Streptococcus  GapC protein corresponding to 
 (a) the amino acid sequences shown at amino acid positions 62 to 81, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;    (b) the amino acid sequences shown at about amino acid positions 102 to 112, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;    (c) the amino acid sequences shown at about amino acid positions 165 to 172, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;    (d) the amino acid sequences shown at about amino acid positions 248 to 271, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20; and    (e) the amino acid sequences shown at about amino acid positions 286 to 305, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20.    
     
     
         6 . The method of  claim 1 , wherein said multiple epitope fusion polypeptide comprises an amino acid sequence having at least 80% sequence identity to the contiguous sequence of amino acids depicted at positions 27-448 of the amino acid sequence depicted in SEQ ID NO:22.  
     
     
         7 . The method of  claim 1 , wherein said multiple epitope fusion polypeptide comprises an amino acid sequence having at least 90% sequence identity to the contiguous sequence of amino acids depicted at positions 27-448 of the amino acid sequence depicted in SEQ ID NO:22.  
     
     
         8 . The method of  claim 1 , wherein said multiple epitope fusion polypeptide comprises an amino acid sequence having at least 95% sequence identity to the contiguous sequence of amino acids depicted at positions 27-448 of the amino acid sequence depicted in SEQ ID NO:22.  
     
     
         9 . The method of  claim 1 , wherein said multiple epitope fusion polypeptide comprises the amino acid sequence of SEQ ID NO:22.  
     
     
         10 . The method of  claim 6 , wherein said multiple epitope fusion polypeptide further comprises a signal sequence.  
     
     
         11 . The method of  claim 9 , wherein said multiple epitope fusion polypeptide further comprises a signal sequence.  
     
     
         12 . The method of  claim 10 , wherein said signal sequence comprises the amino acid sequence depicted at positions 1-26 of SEQ ID NO:22.  
     
     
         13 . The method of  claim 11 , wherein said signal sequence comprises the amino acid sequence depicted at positions 1-26 of SEQ ID NO:22.  
     
     
         14 . An immunodiagnostic test kit for detecting  Streptococcus  infection, said test kit comprising a multiple epitope fusion polypeptide comprising more than one  Streptococcus  GapC epitope from more than one  Streptococcus  species, and instructions for conducting the immunodiagnostic test.  
     
     
         15 . The immunodiagnostic test kit of  claim 14 , wherein said multiple epitope fusion polypeptide comprises a GapC epitope from more than one  Streptococcus  species selected from the group consisting of  Streptococcus dysgalactiae, Streptococcus agalactiae, Streptococcus uberis, Streptococcus parauberis , and  Streptococcus iniae.    
     
     
         16 . The immunodiagnostic test kit of  claim 15 , wherein said multiple epitope fusion polypeptide comprises GapC epitopes from  Streptococcus dysgalactiae, Streptococcus agalactiae  and  Streptococcus parauberis.    
     
     
         17 . The immunodiagnostic test kit of  claim 16 , wherein said multiple epitope fusion polypeptide comprises an epitope from a  Streptococcus  GapC protein corresponding to 
 (a) the amino acid sequences shown at amino acid positions 62 to 81, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;    (b) the amino acid sequences shown at about amino acid positions 102 to 112, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;    (c) the amino acid sequences shown at about amino acid positions 165 to 172, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;    (d) the amino acid sequences shown at about amino acid positions 248 to 271, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20; and    (e) the amino acid sequences shown at about amino acid positions 286 to 305, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20.    
     
     
         18 . The immunodiagnostic test kit of  claim 14 , wherein said multiple epitope fusion polypeptide comprises an amino acid sequence having at least 80% sequence identity to the contiguous sequence of amino acids depicted at positions 27-448 of the amino acid sequence depicted in SEQ ID NO:22.  
     
     
         19 . The immunodiagnostic test kit of  claim 14 , wherein said multiple epitope fusion polypeptide comprises an amino acid sequence having at least 90% sequence identity to the contiguous sequence of amino acids depicted at positions 27-448 of the amino acid sequence depicted in SEQ ID NO:22.  
     
     
         20 . The immunodiagnostic test kit of  claim 14 , wherein said multiple epitope fusion polypeptide comprises an amino acid sequence having at least 95% sequence identity to the contiguous sequence of amino acids depicted at positions 27-448 of the amino acid sequence depicted in SEQ ID NO:22.  
     
     
         21 . The immunodiagnostic test kit of  claim 14 , wherein said multiple epitope fusion polypeptide comprises the amino acid sequence of SEQ ID NO:22.  
     
     
         22 . The immunodiagnostic test kit of  claim 18 , wherein said multiple epitope fusion polypeptide further comprises a signal sequence.  
     
     
         23 . The immunodiagnostic test kit of  claim 21 , wherein said multiple epitope fusion polypeptide further comprises a signal sequence.  
     
     
         24 . The immunodiagnostic test kit of  claim 22 , wherein said signal sequence comprises the amino acid sequence depicted at positions 1-26 of SEQ ID NO:22.  
     
     
         25 . The immunodiagnostic test kit of  claim 23 , wherein said signal sequence comprises the amino acid sequence depicted at positions 1-26 of SEQ ID NO:22.  
     
     
         26 . Antibodies directed against a multiple epitope fusion polypeptide comprising more than one  Streptococcus  GapC epitope from more than one  Streptococcus  species.  
     
     
         27 . The antibodies of  claim 26 , wherein said antibodies are polyclonal.  
     
     
         28 . The antibodies of  claim 26 , wherein said antibodies are monoclonal.

Join the waitlist — get patent alerts

Track US2008009022A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.